2025-08-01 - Analysis Report
Okay, here's a report summarizing the provided information for Merck & Co Inc (MRK), incorporating numerical data, analysis, and relevant context.

## Merck & Co Inc (MRK) Stock Analysis

**Ticker:** MRK
**Company Name:** Merck & Co Inc.
**Company Overview:** Merck & Co Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of a wide range of healthcare products.

### 1. Performance vs. S&P 500 (VOO)

**Key Metrics:**

*   **MRK Cumulative Return:** -10.40%
*   **VOO (S&P 500) Cumulative Return:** 83.19%
*   **Absolute Divergence (Current):** -102.9 (MRK is lagging S&P 500 significantly)
*   **Relative Divergence:** 0.0 (This indicates MRK is at the very bottom end of its historical divergence range compared to VOO)
*   **Divergence Range:** max: 23.1, min: -102.9

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta  | Cap(B) |
|------------|--------|--------|---------|-------|--------|
| 2015-2017  | 2.0%   | 0.0%   | 0.0%    | 0.9   | 134.8  |
| 2016-2018  | 33.0%  | 66.4%  | 38.0%   | 0.2   | 183.1  |
| 2017-2019  | 53.0%  | 66.4%  | 30.0%   | 0.2   | 217.9  |
| 2018-2020  | 19.0%  | 66.4%  | -8.0%   | 0.1   | 196.0  |
| 2019-2021  | -2.0%  | 65.6%  | -51.0%  | 0.0   | 192.4  |
| 2020-2022  | 13.0%  | 69.4%  | 6.0%    | 0.0   | 278.6  |
| 2021-2023  | 31.0%  | 69.4%  | 11.0%   | 0.2   | 273.8  |
| 2022-2024  | -7.0%  | 69.4%  | -34.0%  | 0.2   | 249.8  |
| 2023-2025  | -64.0% | 62.0%  | -112.0% | 0.4   | 196.2  |

**Analysis:**

*   MRK has significantly underperformed the S&P 500.
*   The very low Relative Divergence indicates this underperformance is at a historical extreme.
*   Alpha is mostly negative, indicating that MRK generates lower returns than predicted by the market.
*   Beta is lower than 1, meaning that the stock price is theoretically less volatile than the market.
*   The negative CAGR in recent years and associated negative Alpha suggest that MRK has been unable to generate excess returns above the market risk-free rate in the selected time periods.

### 2. Recent Stock Price Movement

*   **Current Price:** \$78.12
*   **Previous Close:** \$81.75
*   **Change:** -\$4.44
*   **5-Day Moving Average:** \$82.25
*   **20-Day Moving Average:** \$82.31
*   **60-Day Moving Average:** \$79.76

**Analysis:**

*   The current price is below all the moving averages, indicating a recent downward trend.
*   The price decline from the previous close suggests strong recent selling pressure.
*   The 5-day and 20-day moving averages being close together and both above the current price highlight a potential resistance level around \$82.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 35.82 (Approaching oversold territory)
*   **PPO:** -0.45 (Bearish signal, indicating a downward trend)
*   **Hybrid Signal:** cash_60%_Sell 59.9% of holdings (882 shares - Caution - MRI:0.33) (Cash Ratio: 60% on 2025-07-31)
*   **20-Day Relative Divergence Change:** 0.0 (Short-term decrease)
*   **Expected Return:** -1157.4% (Significant underperformance vs S&P 500 over a long-term investment horizon)

**Analysis:**

*   The MRI suggests a low-risk environment based on this indicator, but the technical indicators paint a more concerning picture.
*   The RSI approaching oversold levels could indicate a potential for a short-term bounce, but further analysis is required to confirm.
*   The PPO confirms the bearish trend.
*   The "Hybrid Signal" suggests a cautious approach, recommending selling a portion of holdings and increasing the cash position, likely driven by the other indicators.
*   The large negative expected return is a strong warning sign, suggesting potential challenges for MRK in outperforming the S&P 500 over the long term.

### 4. Recent News & Significant Events

*   **2025-07-31:** Major business developments, regulatory changes, or market events impacting Merck & Co Inc.
*   **2025-07-28:** Analyst discussion on Merck & Co Inc's performance and outlook within industry trends and global economic factors.
*   **2025-07-29:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-08-01:** Market experts highlighting both risks and opportunities for Merck & Co Inc, advising investors to monitor recent news and company announcements.

**Analysis:**

*   The news snippets indicate that MRK has been subject to notable recent events, including those linked to market volatility.
*   Analyst discussions highlight the importance of understanding Merck's performance within broader industry and economic contexts.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2024-08-05 | 2.15 | 16.11 B$   |
| 2024-05-03 | 1.88 | 15.78 B$   |
| 2025-05-02 | 1.88 | 15.78 B$   |

**Analysis:**

*   The earnings data shows fluctuations in both EPS and revenue.
*   It's important to understand the context of these fluctuations, such as product cycles, research and development costs, and market conditions.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | \$15.53B  | 77.98%        |
| 2024-12-31 | \$15.62B  | 75.50%        |
| 2024-09-30 | \$16.66B  | 75.51%        |
| 2024-06-30 | \$16.11B  | 76.76%        |
| 2024-03-31 | \$15.78B  | 77.56%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-03-31 | \$48.34B  | 10.51%  |
| 2024-12-31 | \$46.31B  | 8.08%   |
| 2024-09-30 | \$44.50B  | 7.09%   |
| 2024-06-30 | \$43.58B  | 12.52%  |
| 2024-03-31 | \$40.36B  | 11.80%  |

**Analysis:**

*   Revenue has shown some variability over the past year.
*   Profit margins have been consistently high, indicating good cost management and pricing power.
*   Equity has been increasing, suggesting that the company is retaining earnings and building capital.
*   ROE has fluctuated, reflecting changes in profitability relative to equity.

### 7. Overall Summary

Based on the provided data, Merck & Co Inc (MRK) is currently facing challenges.

**Key Concerns:**

*   **Significant Underperformance:** MRK has significantly underperformed the S&P 500, reaching a historical low in relative divergence.
*   **Bearish Technical Indicators:** Technical indicators such as PPO and recent moving average behavior signal a downward trend.
*   **Negative Expected Return:** The projected negative return suggests potential difficulties in outperforming the market in the long run.
*   **Recent Stock Volatility:** Analysts are discussing Merck & Co Inc's recent performance and its outlook in the context of industry trends and global economic factors.

**Positive Aspects:**

*   **High Profit Margins:** The company maintains high profit margins, demonstrating efficiency.
*   **Low Risk MRI:** The market risk indicator shows low risk.
*   **Solid Equity Growth:** Equity has been increasing, indicating financial stability.

**Recommendation:**

The data suggests a cautious outlook for MRK. Investors should carefully monitor upcoming news, earnings releases, and analyst reports to assess the company's turnaround potential. The hybrid signal suggests selling a portion of the stock and increasing cash. Further due diligence and monitoring are strongly advised before making investment decisions.
